Kornimate/medical-research-clean huggingface dataset:
do patients with colorectal cancer understand that their family is at risk?

Conditions: Colorectal Cancer

Summary: the purpose of this study is to assess whether patients with colorectal cancer understand that their first-degree relatives are at increased risk of getting the cancer themselves and therefore should be screened early. among patients who do understand the risks to their family, we plan to determine who they identify as the source of their information and whether they have acted upon this information and advised family members to be screened. we hypothesize that many patients with colorectal cancer do not have a correct understanding of the risks to their first-degree relatives and the recommendations that they be screened early. if this hypothesis is shown to be true, it can be used to direct improved and more diligent patient education. this, in turn, will hopefully increase the low screening rates among first-degree relatives, and, thereby, save lives in this high-risk population.

1. the primary physician of patients with colorectal cancer will be contacted and asked permission to contact their patient to discuss his or her understanding of familial risk before patient is contacted. 2. a letter will be sent to all patients prior to being contacted, notifying them that all identifying information will be kept confidential and they may decline to participate at any time. 3. patients will be called and asked a series of questions about their understanding of familial risk of colon cancer, the need for early screening and where they learned what they know. if the patient has lacking knowledge they will be educated. 4. each patient will be sent informational brochures about colon cancer after the phone survey. 5. six months later, the patients will be contacted again and asked a series of questions about their understanding of familial risk of colon cancer and the need for early screening to access how much impact the informational brochures had on their knowledge of cancer risk. patients will be asked one additional demographic question about the highest level of education that they have completed.

Eligibility criteria:
inclusion criteria: patients who were diagnosed with crc and received first treatment here or elsewhere and patients who were diagnosed elsewhere and received their first treatment here. all are currently followed here and still alive. exclusion criteria: patients in the registry who are not followed here, patients with familial adenomatous polyposis, patients with hereditary non-polyposis colorectal cancer, and patients with no siblings or children.

Keywords: colorectal cancer
botulinum toxin injection for sialorrhea in cerebral palsy

Conditions: Sialorrhea

Summary: a 100 units of botulinum toxin was injected in both parotid and submandibular glands for children (2 - 12 years) with incapacitating sialorrhea in juvenile cerebral palsy patients and they are followed up for 1 year

this was a prospective, longitudinal analysis with 1-year follow-up of 52 children with juvenile cerebral palsy (jcp) suffering from sialorrhea enrolled from 3 tertiary pediatric neurology rehabilitation centers (two in cairo and one in alexandria) and subjected to repeated bont-a injection. the recruitment period was between june 30, 2021, until may 1, 2022 (the last patient follow-up ended on april 30, 2023). intervention: 100 units of onabotulinumtoxina (botox®) were injected in the parotid and submandibular glands follow-up visits: mo 1 post-injection (for every injection session) and every 3 months thereafter in each visit; the following efficacy variables were assessed: primary outcome measures: the severity and frequency of sialorrhea evaluated by drooling severity scale (dss), and drooling frequency scale (dfs) and visual-analogic ratings of familial distress (vas-fd). secondary outcome measure: the carers' global impression of change scale score measured on a 7-point likert scale from -3 (very much worse) to +3 (very much improved) also, adverse events were assessed in each visit

Eligibility criteria:
inclusion criteria: * juvenile cerebral palsy with age range (4 - 12 years) * having severe drooling (dfs \> 4) * signing written informed consent by the legal guardians. exclusion criteria: * previous bont-a injection in the last three months * patients receiving systemic medicine for the treatment of sialorrhea in the last 6 weeks * any contraindications to treatment with bont
innate immunity gene polymorphisms and yeast colonization

Conditions: Critical Illness

Summary: it is proposed to carry out the study in three medical or surgical intensive care units (icu) in the chru, lille, and the chu, besançon. in all patients admitted to these icu (see figure 2), a corrected index of colonisation (cic) will be determined and blood samples will be taken for genotyping of the lectins mbl, dectin-1 and galectin-3 and for serology. over the duration of hospitalisation (on average 28 days) and weekly, fungal colonisation will be assessed in all patients (according to the cic), and antibodies to yeast glycans will be determined by a simultaneous multiparametric analysis involving several families of natural or synthetic antigens, and the detection of circulating antigens (mannan and β-1,3 glucan).

determination of the cic: the cic will be determined on admission and then once a week during hospitalisation. this will be carried out on a fixed day for all patients; we will avoid determining the cic any closer than 2 days apart. it is not planned in this study to modify the therapeutic strategy of the icu services. the strains isolated will be stored in glycerol solution at -80°c. the specimens for genetic and serological analysis will be stored centrally in a local mycology laboratory. genotyping of lectin genes and tlrs: two tubes containing 6 ml of blood in edta will be taken from each patient for extraction of dna serological study, detection of antibodies to yeast glycans: 10 ml of whole blood will be taken from each patient on the day of inclusion and over the duration of hospitalisation (maximum total quantity of 40 ml). this will be done on a fixed day for all patients; we will avoid sampling any closer than 2 days apart. functional tests on peripheral blood mononuclear cells (pbmcs) taking into account the fact that the results of genotyping will not be available in real time and the need to work with freshly collected cells, a group size of 50 patients in group 2 (negative cic over the duration of hospitalisation) and 50 patients in group 3 (negative cic at admission but positive at hospital discharge) will be analysed. stimulation tests will be carried out in the presence of whole yeasts or yeast extracts on sub-populations of cells isolated from 20 ml of peripheral blood in edta.

Eligibility criteria:
inclusion criteria: * male or female patients, ≥18 years of age, admitted to medical or surgical icu for a duration of \>48 h, irrespective of their colonisation status. exclusion criteria: * -patient (or their representative) who refuses to participate in the study or to undergo the procedures required for the investigations (mycological sampling in order to determine the cic, blood sampling for genotyping of dna and for serology) * previous antifungal treatment (in the 15 days preceding admission to the icu). * a cic value based on an insufficient number of sampled sites (\<6). * neutropenic patients * patients who are receiving immunosuppressants (transplanted, grafted...) * patients who do not have universal cover or social security cover

Keywords: genetic susceptibility candida infection colonization
preoperative dry lean body mass as a prognostic factor for excess weight loss after bariatric surgery.

Conditions: Bariatric Surgery Candidate

Summary: bariatric surgery is currently the only method that has proven long-term effectiveness in obesity. although the benefit of physical activity on weight loss has been demonstrated, no correlation has ever been reported between preoperative lean body mass and postoperative weight loss. dry lean mass is probably an essential prognostic factor for the effectiveness of bariatric surgery. the main objective of this study is to define a preoperative dry lean body mass threshold as a worst prognostic factor for weight loss one year after bariatric surgery. the management of patients included in this study was modelled on the management usually offered to patients followed for the same pathology in the diabeto-endocrinology department. there are no study-specific examinations that are not part of current practice.


Eligibility criteria:
inclusion criteria: * bmi ≥ 40 or bmi ≥ 35 kg/m2 and a complication that can be improved after bariatric surgery: cardiovascular disease including hypertension, severe metabolic disorder including type 2 diabetes, sleep apnea syndrome or other severe respiratory disorder, hepatic steatosis, disabling osteoarticular disease. * patient requiring bariatric surgery (sleeve-gastrectomy or gastric bypass) * patient who has agreed to participate in the study * patient with social security coverage. exclusion criteria: * patient with a contraindication to bariatric surgery (cognitive or psychological disorders, severe eating disorders, addiction to alcohol or psychoactive substances, contraindication to general anaesthesia, multiple history of digestive surgery, high risk of undernutrition (progressive cancer, chronic inflammatory bowel disease, cirrhosis, severe renal insufficiency...) * pregnant or lactating women * minor patient * major patient under tutorship, curatorship, or deprived of liberty * patient unable to understand protocol and / or give express consent * patient not affiliated with a social security system or beneficiary of such a scheme * patient participating in an intervention-type clinical research protocol likely to modify the evaluations of this protocol * adults under the protection of justice

Keywords: lean body mass bariatric surgery
feasibility study: ulthera treatment of the buttocks and thighs

Conditions: Skin Laxity

Summary: up to 30 subjects will be enrolled. enrolled subjects will receive an ulthera® treatment to one side of the body, treating the lateral buttock region. follow-up visits will occur at 90 and 180 days post-treatment. study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

this is a prospective, single-center, pilot clinical trial to evaluate the efficacy of the ulthera® system to improve buttock and thigh skin laxity. global aesthetic improvement scale scores and patient satisfaction questionnaires will be obtained.

Eligibility criteria:
inclusion criteria: * male or female, age 30 to 65 years. * subject in good health. * skin laxity in the buttocks and thighs. * understands and accepts the obligation not to undergo any other procedures in the areas to be treated and/or weight loss through the follow-up period. * willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. * subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at visit 1 and be willing and able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, iud, surgical sterilization, abstinence) during the study. women will not be considered of childbearing potential if one of the following conditions is documented on the medical history: a) postmenopausal for at least 12 months prior to study; b) without a uterus and/or both ovaries; or c) a bilateral tubal ligation at least six months prior to study enrollment. exclusion criteria: * presence of an active systemic or local skin disease that may affect wound healing. * bmi equal to or greater than 40. * excessive subcutaneous fat in the buttocks and thighs. * excessive skin laxity in the buttocks and thighs. * significant weight fluctuation (±10 lbs) in the past 6 months. * taking weight-loss medications/supplements. * surgical or non-surgical treatments to the target areas in the last 12 months, e.g., liposuction. * inability to understand the protocol or to give informed consent.

Keywords: ulthera® system ultherapy™ treatment ulthera, inc. ultrasound treatment for skin tightening
procalcitonin-guided antibiotic therapy during severe exacerbation of copd

Conditions: Acute Exacerbation Copd

Summary: this study assess whether a procalcitonin guided antibiotic therapy can reduce significantly unnecessary antibiotic prescription during severe exacerbation of copd requiring mechanical ventilation without compromising patients' outcome. the first group of patients will receive systematically empiric antibiotic therapy and the second group will receive antibiotics only if procalcitonin value is at or greater than 0.25 ng/ml.

recently, procalcitonin gained interest as the most reliable biomarker in predicting bacterial origin in low respiratory tract infections and sepsis. procalcitonin was shown to be non-inferior to standard guidelines in guiding antibiotic therapy during copd exacerbation, without worsening patients' outcomes, and with a significant reduction in antibiotic exposure. its use to guide antibiotic treatment during copd exacerbation may be more challenging because of the frequent colonization of the airways in patients with copd, and thus it needs further evaluation. additionally, until today, no interventional studies evaluating procalcitonin protocol have been conducted in ventilated copd patients.

Eligibility criteria:
inclusion criteria: * patients \> 40 years old who consent to the study protocol * copd diagnosis based on gold guidelines exclusion criteria: * patients who did not consent * asthma * malignancy * immunocompromised * survival for at least 1 year is unlikely * patients already enrolled in this study

Keywords: procalcitonin mechanical ventilation copd exacerbation
18f-ftc-146 pet/ct in newly-diagnosed osteosarcoma

Conditions: Osteosarcoma

Summary: the purpose of this research is to evaluate the study drug, 18f ftc-146, as a positron emission tomography (pet) / computed tomography (ct) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

primary objective: demonstrate correlation of pre-post reduction in 18f-ftc-146 pet/ct with amount of post-treatment tumor necrosis in newly-diagnosed and treated osteosarcoma patients. secondary objective: demonstrate correlation of pre-post reduction in 18f-ftc-146 pet/ct with amount of post-treatment pain reduction in newly-diagnosed and treated osteosarcoma patients.

Eligibility criteria:
inclusion criteria: * patients with biopsy proven osteosarcoma requiring local surgical intervention. * ecog ≤ 2 * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * chemotherapy in the past 2 months. * prior history of allergic reaction to 18f ftc 146. * pregnant or nursing
music therapy on neutrophyl lymphocytes ratio, interleukin 6 and interleukin 10 levels of burnout syndrome

Conditions: Burnout Syndrome; Neutrophil-Lymphocyte Ratio; Interleukin-6; Interleukin-10

Summary: burnout syndrome (bos) can be defined as a state of stress both physically and psychically due to the burden and stressor of high work. the prevalence of bos in health workers varies between 25-75% globally. studies have shown that the presence of burnout syndrome will meaningfully reduce the quality of services related to patient safety and cause immune system disorders that act as the body's defense against viral, bacterial, protozoal and fungal infections. many strategies have been researched to help prevent and reduce the occurrence of burnout syndrome, one of which is music therapy. the purpose of this study was to determine the effect of music therapy on the immune response in health workers with burnout syndrome. this study is a randomized clinical trial with a pre and post test control group design for health workers at dr kariadi general hospital and dr. cipto mangunkusumo general hospital. subjects will be provided with information prior to the study and asked to sign an informed consent sheet if they agree to be involved in the study. subjects will be divided into control groups and treatment groups with matching age, gender and type of work. in the treatment group, music therapy will be given as much as 3 times a week for 4 weeks. data were taken on both groups before and after the intervention. this study used the maslach burnout inventory human service survey (mbi-hss) and blood laboratory examination to determine the value of the neutrophyl lymphocyte ratio, interleukin 6 and interleukin 10 levels.


Eligibility criteria:
inclusion criteria: 1. age 18 years - 60 years old 2. health workers in the wards and polyclinic of dr. cipto mangunkusumo hospital or dr. kariadi hospital, including doctors in charge of patients, nurses, residents, and other supporting health workers 3. included in the burnout syndrome criteria from the maslach burnout inventory-human service survey questionnaire exclusion criteria: 1. refusing to follow the study 2. have a history of heart disease, kidney disease, diabetes, cancer, tuberkulosis, autoimmune, immunodeficiency 3. taking drugs that affect the central nervous system or immunosuppressants 4. have hearing disorder 5. have a psychiatric disorder 6. being pregnant 7. healthcare workers who don't like music
evaluation of the efficacy and safety of mv130 in chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of the study is to evaluate the efficacy and safety of a biological vaccine (mv130 in subjects with chronic obstructive pulmonary disease (copd) compared with a placebo group.

double blind parallel placebo controlled study. the subjects will receive medication during 12 months and will be followed up during another six months

Eligibility criteria:
inclusion criteria: * written informed consent. * both gender * age between 35 and 85. * must be able to follow the treatment regimen * diagnosis of moderate copd according to gold criteria * consumption of 10 or more packs of cigarettes/year * fertile women of must use an approved contraceptive method exclusion criteria: * pregnant women, breastfeeding * subject who has participated in a study or clinical trial with an investigational product in the last 3 months before inclusion * subject with severe copd * subject with a history of hypersensitivity to any component of the vaccine * subject outside of age range * subject diagnosed with asthma * subject who has had an exacerbation 4 weeks before starting the trial. * subject that have needed corticosteroids in the last 4 weeks before starting the trial * subject diagnosed with primary or secondary immunodeficiency subjects with chronic lymphoproliferative disease * subjects with chronic infectious disease * subject with chronic heart disease, arrhythmias, or episodes of arrhythmia secondary to the administration of bronchodilators. * subject diagnosed with copd and chronic colonization by pseudomonas aeruginosa

Keywords: vaccine chronic obstructive pulmonary disease (copd)
cumulative live birth rate of patients at high risk of ohss after freeze-all embryos at cleavage or blastocyst stage

Conditions: Infertility

Summary: ovarian stimulation for the induction of multifollicular growth by gonadotrophins represents an important part of in vitro fertilization (ivf). however, the use of these drugs can be associated with side effects, from which the most common is the ovarian hyperstimulation syndrome (ohss). stimulation with gonadotrophins in a gonadotropin-releasing hormone (gnrh) antagonist cycle rather than a gnrh agonist cycle reduces significantly the risk of ohss. during stimulation, the best predictor of severe ohss is the number of follicles \>10mm on the day of triggering final oocyte maturation, with the threshold at ≥16 follicles. when this occurs, final oocyte maturation can be induced with a gnrh agonist, reducing further the risk the syndrome. to perform a fresh embryo transfer, 1500 iu human chorionic gonadotropin (hcg) can be administered on the day of oocyte retrieval for the luteal support. however, with this procedure there are still some cases of ohss. to overcome this, it is suggested to combine gnrh agonist triggering with a freeze-all embryos strategy and perform embryo replacement in subsequent frozen-thawed embryo transfer (fet) cycles. different cryopreservation strategies are been performed according to the procedure of each fertility center, such as cryopreservation at 2 pronuclear (2pn), cleavage or blastocyst stage. the aim of this study is to determine the optimal strategy for the freeze-all cycles and particularly the optimal day for freezing, thawing and transferring the embryos. the hypothesis is that there will increased cumulative live birth rates per started cycle in blastocyst compared to cleavage stage fet cycles.


Eligibility criteria:
inclusion criteria: * patients \<40 years old * indication for in vitro fertilisation (ivf)/intracytoplasmic sperm injection (icsi) * no more than 2 previous failed ivf/icsi cycles * stimulation in gnrh antagonist cycle * presence of ≥16 follicles of \>10mm on the day of triggering of final oocyte maturation * gnrh agonist trigger (triptorelin 0.2mg) exclusion criteria: * cycles with testicular sperm extraction * preimplantation genetic diagnosis * patients with uterine malformations * patients with infectious diseases

Keywords: ohss agonist trigger freeze-all blastocyst cleavage
can ideal mesh size be standardized in open inguinal hernia repair

Conditions: Inguinal Hernia

Summary: two hundred consecutive unilateral inguinal hernia patients will be included in the study. patients will be recorded by measuring the distance between the pubic tubercle and the deep inguinal ring, the distance between the inguinal ligament and the internal oblique aponeurosis, the distance between the deep and superficial inguinal ring diameters and their anterior superior iliac spine. the contribution of these measures to the determination of the ideal mesh size will be analyzed.

this prospective study includes 200 consecutive male patients who underwent unilateral open inguinal hernia repair since march 2020. under-18 hernias, complicated hernias, recurrent hernias, and those with laparoscopic hernia repair will be excluded. initially, the distance between the pubic tubercle and the medial edge of the deep inguinal ring will be measured. next, the distance between the inner edge of the inguinal ligament and the upper level of the internal oblique aponeurosis will be measured at the hesselbach triangle. hesselbach triangle area will be calculated. the diameter of the superficial and deep inguinal ring and their spina iliaca anterior superior (sias) distance will be measured. the contribution of these measures to the determination of the ideal mesh size will be analyzed.

Eligibility criteria:
inclusion criteria: * male patients over 18 years of age who applied for inguinal hernia surgery exclusion criteria: * patients under the age of 18 * complicated hernias * recurrent hernias * those undergoing laparoscopic hernia repair